Eton Pharmaceuticals (ETON) Other Non-Current Liabilities (2017 - 2025)
Eton Pharmaceuticals (ETON) reported Other Non-Current Liabilities of $5.2 million for Q4 2025, up 186.39% on a YoY basis from $1.8 million in Q4 2024, and up 32.95% sequentially from $3.9 million in Q3 2025.
Eton Pharmaceuticals (ETON) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Eton Pharmaceuticals (ETON) has 4 years of Other Non-Current Liabilities data on file, last reported at $5.2 million in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 186.39% year-over-year to $5.2 million; the trailing twelve-month figure through Dec 2025 stood at $5.2 million (up 186.39% YoY), and the FY2025 full-year result was $5.2 million, up 186.39% from the prior year.
- Other Non-Current Liabilities rose to $5.2 million in Q4 2025, from $3.9 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $5.2 million in Q4 2025 to a low of $1.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Eton Pharmaceuticals | 1.19 Bn | 1.16 Bn | 13.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.24 Mn |
| Sep 30, 2025 | 3.94 Mn |
| Jun 30, 2025 | 4.27 Mn |
| Mar 31, 2025 | 4.15 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2018 | 1.58 Mn |
| Dec 31, 2017 | 520,000.00 |